Semin Thromb Hemost 2013; 39(02): 117-126
DOI: 10.1055/s-0032-1333536
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Novel Oral Anticoagulants

Cristhiam M. Rojas-Hernandez
1  Division of Hematology/Oncology, University of New Mexico, Albuquerque, New Mexico
David A. Garcia
2  Division of Hematology, University of Washington, Seattle, Washington
› Author Affiliations
Further Information

Publication History

Publication Date:
06 February 2013 (online)


After the introduction of warfarin, long-term oral anticoagulation treatment remained unchanged for more than 50 years. Most recently, with the development and approval of new oral anticoagulants, the treatment of medical conditions that require thrombosis prophylaxis and long-term anticoagulation has become more complex. In the case of venous thromboembolism (VTE) prevention after orthopedic surgery, the new oral agents will be less costly than the parenteral alternative. In other settings (such as atrial fibrillation or treatment of acute VTE), the new agents will offer additional convenience at higher cost, but the degree to which they will reduce clinically important events such as thrombosis or bleeding will be limited, especially for patients on optimally controlled warfarin. As the use of the new oral anticoagulants becomes more widespread, it will be important for all clinicians to have a basic understanding of their pharmacology, advantages, and limitations. Although the need to measure or reverse the effect of these drugs will arise infrequently, clinicians—especially hematologists—will desire evidence-based recommendations about how to manage such scenarios, which will require research studies.